Amarin announces senior management changes

Connecticut firm appoints ceo, president and principal accountant

Amarin Corporation, a US clinical-stage biopharmaceutical company with a focus on cardiovascular disease, has appointed Joseph Zakrzewski as chief executive. He will continue to serve as chairman of the board.

Zakrzewski has more than 20 years of experience, including holding the position of chief operating officer of Reliant Pharmaceuticals when Omacor/Lovaza was developed and acquired in 2007 by GlaxoSmithKline. He was most recently chief executive of Xcellerex, a Massachusetts-based biotechnology company. Although he currently serves on the boards of directors and in other advisory roles for various companies, Amarin is his primary business commitment.

Additionally, John Thero has been promoted to Amarin’s president. Since November 2009, he has been the company’s chief financial officer.

Prior to joining Amarin, Thero was chief financial officer at ViaCell, where he helped guide the sale of the company, and Abiomed, during its transition from a development-stage company into a commercial entity.

Colin Stewart, who was Amarin’s president and ceo, resigned last month to address personal matters.

In connection with these changes, Frederick Ahlholm, vice president finance, has become the company’s principal accounting officer.

You may also like

Manufacturing

Rezon Bio launches as European biologics CDMO with mirrored sites in Poland

New CDMO combines cost efficiency, digital innovation and EMA/FDA-audited facilities in Gdańsk and Warsaw to accelerate biologics development and commercialisation
Manufacturing

Baxter earns first Gold Resiliency Badge from HIRC across IV, nutrition and premix drug categories

The company is the first manufacturer to receive the Healthcare Industry Resilience Collaborative’s gold badge for IV solutions, nutrition solutions and premix drugs, recognising its leadership in building a transparent, reliable and disruption-ready healthcare supply chain
Analysis

From West to East: building biotech bridges across APAC and the Middle East

Amid rising geopolitical uncertainty, US biotech companies are looking beyond tariffs and trade tensions to expand into Asia-Pacific and the Middle East
Distribution

Er-Kim partners with Sentynl Therapeutics to expand access to ultra-rare disease treatments Nulibry and Zokinvy

The collaboration aims to provide timely access to these EMA- and FDA-approved therapies for patients with life-threatening ultra-rare conditions, including molybdenum cofactor deficiency Type A and Hutchinson-Gilford Progeria Syndrome
Manufacturing

Gerresheimer and Portal Instruments team up to commercialise PRIME Nexus reusable autoinjector

Gerresheimer and Portal Instruments are joining forces to develop and manufacture the PRIME Nexus syringe-based, reusable, connected autoinjector platform, offering pharmaceutical companies an end-to-end solution for delivering chronic disease therapies
Pharmaceutical

Biognosys expands multiomic capabilities with biocrates metabolomics and lipidomics for drug discovery

The expansion provides biopharma and clinical researchers with a scalable, high-precision multiomics platform to support drug discovery and biomarker research delivering deeper insights into complex biological systems
Finance

Pfizer to acquire Metsera in $4.9bn deal, expanding obesity drug pipeline with next-generation incretin and amylin therapies

The deal strengthens Pfizer’s position in the fast-growing obesity market, with additional milestone payments of up to $2.3bn tied to key clinical and regulatory achievements
Subscribe now